About this document

Vaxcyte - VAX-24 Phase 1 2 Proof-Of-Concept Data - 2022.10.24 by Andrew Maize is a document available to read on EtoBox.

The VAX-24 Phase 1/2 study demonstrated a safety profile comparable to Prevnar 20 and met or exceeded immunogenicity standards for all 24 serotypes, with an optimal 2.2mcg dose advancing to Phase 3. Vaxcyte plans to pursue Breakthrough Therapy Designation and expects to submit an infant IND application and initiate a Phase 2 study in early 2023. The pneumococcal vaccine market is projected to grow significantly, driven by increased demand for broader coverage and the introduction of new vaccines like VAX-24

Author

Andrew Maize

Language

EN